ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Financial Statements and Exhibits

ANTHERA PHARMACEUTICALS, INC. (NASDAQ:ANTH) Files An 8-K Financial Statements and Exhibits
Item 9.01.

Story continues below

Financial Statements and Exhibits.

(d) Exhibits.




Press release dated March 12, 2018

Anthera Pharmaceuticals Inc Exhibit
EX-99.1 2 ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Anthera Pharmaceuticals Reports Top Line Data from the RESULT Phase 3 Clinical Study of Sollpura – Sollpura did not achieve the primary endpoint of the coefficient of fat absorption (“CFA”) – Sollpura did achieve the secondary endpoint of coefficient of nitrogen absorption (“CNA”) – Further development of Sollpura to be discontinued – Anthera to evaluate all strategic alternatives – Anthera to host teleconference today at 8:30 am ET HAYWARD,…
To view the full exhibit click here


Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

An ad to help with our costs